Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis

Pedro Nazareth Aguiar; Hakaru Tadokoro; Gislaine Fernandes Da Silva; Mayndra Mychelle Landgraf; Carmelia Maria Noia Barreto; Bruno Andraus Filardi; Gilberto De Lima Lopes; Pedro Oliveira; Ramon Andrade De Mello

doi:10.2217/fon-2016-0068

Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis

Pedro Nazareth Aguiar, Hakaru Tadokoro, Gislaine Fernandes Da Silva, Mayndra Mychelle Landgraf, Carmelia Maria Noia Barreto, Bruno Andraus Filardi, Gilberto De Lima Lopes, Pedro Oliveira, Ramon Andrade De Mello

Research output: Contribution to journal › Article

Abstract

Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. Results: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). Conclusion: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.

Original language	English (US)
Pages (from-to)	2755-2764
Number of pages	10
Journal	Future Oncology
Volume	12
Issue number	23
DOIs	https://doi.org/10.2217/fon-2016-0068
State	Published - Dec 1 2016
Externally published	Yes

Keywords

carboplatin
chemoradiotherapy
chemotherapy
cisplatin
head and neck

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2016-0068

Fingerprint Dive into the research topics of 'Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis'. Together they form a unique fingerprint.

Cite this

Definitive chemoradiotherapy for squamous head and neck cancer : Cisplatin versus carboplatin? A meta-analysis. / Aguiar, Pedro Nazareth; Tadokoro, Hakaru; Da Silva, Gislaine Fernandes; Landgraf, Mayndra Mychelle; Noia Barreto, Carmelia Maria; Filardi, Bruno Andraus; Lopes, Gilberto De Lima; Oliveira, Pedro; De Mello, Ramon Andrade.

In: Future Oncology, Vol. 12, No. 23, 01.12.2016, p. 2755-2764.

Research output: Contribution to journal › Article

Aguiar, Pedro Nazareth ; Tadokoro, Hakaru ; Da Silva, Gislaine Fernandes ; Landgraf, Mayndra Mychelle ; Noia Barreto, Carmelia Maria ; Filardi, Bruno Andraus ; Lopes, Gilberto De Lima ; Oliveira, Pedro ; De Mello, Ramon Andrade. / Definitive chemoradiotherapy for squamous head and neck cancer : Cisplatin versus carboplatin? A meta-analysis. In: Future Oncology. 2016 ; Vol. 12, No. 23. pp. 2755-2764.

@article{3d2391a2476c4a728ef28542b8c63bbe,

title = "Definitive chemoradiotherapy for squamous head and neck cancer: Cisplatin versus carboplatin? A meta-analysis",

abstract = "Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. Results: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). Conclusion: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.",

keywords = "carboplatin, chemoradiotherapy, chemotherapy, cisplatin, head and neck",

author = "Aguiar, {Pedro Nazareth} and Hakaru Tadokoro and {Da Silva}, {Gislaine Fernandes} and Landgraf, {Mayndra Mychelle} and {Noia Barreto}, {Carmelia Maria} and Filardi, {Bruno Andraus} and Lopes, {Gilberto De Lima} and Pedro Oliveira and {De Mello}, {Ramon Andrade}",

year = "2016",

month = dec,

day = "1",

doi = "10.2217/fon-2016-0068",

language = "English (US)",

volume = "12",

pages = "2755--2764",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "23",

}

TY - JOUR

T1 - Definitive chemoradiotherapy for squamous head and neck cancer

T2 - Cisplatin versus carboplatin? A meta-analysis

AU - Aguiar, Pedro Nazareth

AU - Tadokoro, Hakaru

AU - Da Silva, Gislaine Fernandes

AU - Landgraf, Mayndra Mychelle

AU - Noia Barreto, Carmelia Maria

AU - Filardi, Bruno Andraus

AU - Lopes, Gilberto De Lima

AU - Oliveira, Pedro

AU - De Mello, Ramon Andrade

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. Results: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). Conclusion: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.

AB - Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. Results: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). Conclusion: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.

KW - carboplatin

KW - chemoradiotherapy

KW - chemotherapy

KW - cisplatin

KW - head and neck

UR - http://www.scopus.com/inward/record.url?scp=84995451004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995451004&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0068

DO - 10.2217/fon-2016-0068

M3 - Article

C2 - 27549331

AN - SCOPUS:84995451004

VL - 12

SP - 2755

EP - 2764

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 23

ER -